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ABSTRACT
Objective To compare characteristics, pregnancies and
treatments during pregnancies of seronegative and
seropositive antiphospholipidsyndrome (APS), to analyse
factors associated with obstetrical outcome.
Patients and methods Inclusion criteria were: (1)
thrombotic and/or obstetrical APS (Sydney criteria); (2)
absence of conventional antiphospholipid antibodies (APL);
(3) at least one persistent non-conventional APL among IgA
anticardiolipin antibodies, IgA anti-B2GPI, anti-vimentin G/
M, anti-annexin V G/M, anti-phosphatidylethanolamine G/M
and anti-phosphatidylserine/prothrombin G/M antibodies.
The exclusion criteria were: (1) systemic lupus
erythematosus ( SLE) or SLE-like disease; and (2) other
connective tissue disease.
Results A total of 187 women (mean 33±5 years) with
seronegative APS were included from 14 centres in Austria,
Spain, Italy, Slovenia and France and compared with 285
patients with seropositive APS. Seronegative APS has more
obstetrical rather than thrombotic phenotypes, with only 6%
of venous thrombosis in comparison to seropositive APS.
Cumulative incidence of adverse obstetrical events was
similar in seronegative and seropositive APS patients,
although higher rates of intrauterine deaths (15% vs 5%;
p=0.03), of preeclampsia (7% vs 16%, p=0.048) and lower
live birth term (36±3 vs 38±3 weeks of gestation; p=0.04)
were noted in seropositive APS. The cumulative incidence of
adverse obstetrical events was significantly improved in
treated versus untreated seronegative APS (log rank<0.05),
whereas there was no difference between patients who
received aspirin or aspirin-low-molecular weightedheparin
combination.
Conclusion Several non-criteria APL can be detected in
patients with clinical APS features without any conventional
APL, with various rates. The detection of non-criteria APL
and thus the diagnosis of seronegative APS could discuss
the therapeutic management similar to seropositive APS,
but well-designed controlled studies are necessary.
INTRODUCTION
Antiphospholipid syndrome (APS) is an auto-
immune disease characterised by vascular
thrombosis, various obstetrical adverse events
and persistent antiphospholipid antibodies
(APL). The conventional APL includes lupus
anticoagulant (LA), IgG/M anticardiolipin
antibodies (aCL) and IgG/M antibodies
against β2GPI (anti-β2GPI) antibodies.1 Sero-
negative APS has been recently defined in
patients with obstetrical and thrombotic clini-
cal APS features (Sydney criteria), but without
detectable conventional APL.2 In seronegative
APS, the possibility of persistent non-criteria
APL has been raised. Several non-criteria anti-
phospholipid antibodies, such as IgA aCL and
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What is already known about this subject?
► Several studies reported about seronegative APS
mainly defined by clinical criteria and among them
the series with clinical criteria and at least one
positive non-criteria APL are lacking.
What does this study add?
► Several non-criteria APL can be detected in patients
with clinical features consistent with APS without any
conventional APL, with various prevalent rates.
How might this impact on clinical practice?
► The detection of non-criteria APL and thus the
diagnosis of seronegative APS could discuss the
therapeutic management similar to seropositive
APS, but well-designed controlled studies are
necessary.
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vimentin and anti-annexin V and II antibodies can actually
be tested.3–6 However, there is a paucity of studies evaluat-
ing the link between these autoantibodies and clinical
status, in particular for obstetrical outcomes.7 Studies
mostly evaluated the prevalence of these persistent non-
criteria APL in thrombotic clinical subsets, showing
10–15% of prevalent among patients with unexplained
venous thrombosis. Accurate identification of patients
with APS is essential, as treatment during pregnancy sig-
nificantly improves the fetal and maternal outcomes.8 Stu-
dies reporting pregnancy outcomes in seronegative
clinical APS with presence of non-criteria APL, treatments
and comparison of this condition to seropositive APS are
still lacking. From this retrospective European study we
aimed to (1) describe the clinical and laboratory features
of seronegative clinical APS with detectable persistent non-
criteria APL; (2) describe the fetal, maternal outcomes
and the treatments during pregnancies; (3) compare ser-
onegative APS to seropositive APS women and (4) analyse
factors associated with adverse obstetrical outcomes in
seronegative and seropositive APS.
PATIENTS AND METHODS
Patients’ selection
A retrospective study was initiated with the European
Forum on Antiphospholipid Antibodies from 2017 to
2019 and all practitioners were asked to fill
a standardised excel form.
Inclusion criteria were: (1) arterial and/or venous
thrombotic; and/or obstetrical primary clinical APS (Syd-
ney criteria) (not explained by usual causes, p.e. chromo-
somal, uterine, hormonal, etc., abnormalities for
recurrent miscarriages); (2) absence of conventional
antiphospholipid antibodies; (3) presence of at least
one persistent non-conventional APL among IgA aCL,
IgA anti-β2GPI, anti-vimentin G/M, anti-annexin V G/
M, anti-PE G/M, anti-PS/PT G/M antibodies and (4) at
least one pregnancy after the diagnosis of seronegative
APS. The clinical APS criteria for thrombosis were other-
wise unexplained thrombosis and for obstetrical events
recurrent unexplained early miscarriages, unexplained
intrauterine deaths and/or preeclampsia and prematur-
ity from placental insufficiency otherwise unexplained.
The exclusion criteria were: (1) associated systemic
lupus erythematosus (SLE) or SLE-like disease (SLE fea-
tures and/or positive antinuclear autoantibodies) and
(2) other systemic connective tissue disease (Sjogren’s
syndrome, systemic sclerosis, myositis, etc.).
Maternal age, characteristics of previous thrombosis and
obstetrical features, associated thrombotic and cardiovas-
cular factors (obesity, hypercholesterolaemia, tobacco use,
diabetes mellitus, arterial hypertension, constitutional
thrombophilia), course and outcome of previous pregnan-
cies and treatments during the pregnancies were
recorded. Adverse pregnancy outcomes included early
miscarriage (<10 weeks of gestation), fetal loss (≥10 weeks
of gestation), intra-uterine growth restriction (IUGR), pre-
maturity (<34 weeks of gestation), pre-eclampsia or
eclampsia, hemolysis, elevated liver enzymes and low plate-
let count (HELLP) syndrome, placental abruption, gesta-
tional arterial hypertension and arterial and/or venous
thrombosis during the pregnancy. All these data were
included in standardised electronic files which were filled
by the practitioner of each patient.
Non-criteria APL testing included anti-β2GPI IgA, anti-
annexin V antibodies, anti-PE IgG and IgM antibodies,
anti-PS/PT IgG and IgM antibodies, IgA aCL or anti-
vimentin antibodies. For patients with at least one positive
non-criteria APL, non-criteria APL positivity was con-
firmed to be persistent at 12 weeks. Because of non-
standardisd tests for seronegative APL, APL were
expressed as positives or negatives at 99° percentiles, with-
out considering the titers.
The control group was selected among women with
primary seropositive APS (Sydney criteria), included in
the French APS and Lupus Registry. This registry retro-
spectively included APS patients, mainly in two referral
centres (Cochin and Lille hospitals). The exclusion cri-
teria were the same as for the seronegative APS: (1)
associated SLE or SLE-like disease (SLE features and/or
positive antinuclear autoantibodies) and (2) other sys-
temic connective tissue disease (Sjogren’s syndrome, sys-
temic sclerosis, myositis, etc.). For the first analysis
comparing phenotypes among seropositive and serone-
gative APS patients, we selected all APS women included
in the registry, including obstetrical and thrombotic APS
phenotypes and excluding SLE-associated APS. For the
comparison of subsequent pregnancies following APS
diagnosis, we only selected women with seropositive APS
(obstetrical and/or thrombotic phenotype), who had at
least one registered pregnancy after the APS diagnosis
similarly to the seronegative APS women.
Statistical analysis
Descriptive analyses were expressed as proportions (%)
for categorical variables and means (SD) for continuous
variables. First, we compared phenotypes from all serone-
gative and seropositive APS patients, using t-tests for con-
tinuous variables and Chi-squared tests for categorical
variables. Then, we compared the pregnancy outcomes
occurring after APS diagnosis. To study obstetrical out-
comes, we chose the following outcomes: fetal loss
<10 weeks, fetal loss ≥10 weeks, premature birth
<34 weeks of gestation, maternal complications (HELLP
and/or preeclampsia, thrombosis) and the presence of
any of these events. To assess the association between APL
status and obstetrical outcomes, univariate analyses were
performed using t-tests for continuous variables, and chi-
squared tests for categorical variables. We subsequently
used multivariate models using logistic regressions, with
all variables associated with the outcome (p<0.2) in uni-
variate analyses. In those analyses, missing variables were
imputed using multiple imputations. Kaplan–Meier
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curves and log-rank tests were used to compare the cumu-
lative incidence of adverse obstetrical events first accord-
ing to the treatment among seronegative APS, then
comparing seronegative and seropositive APS. All ana-
lyses were performed using R software, version 3.4.2 (R
Foundation for Statistical Computing, Vienna, Austria).
RESULTS
A total of 187 women (mean age 33±5 years) with serone-
gative APS were included from 14 centres in Austria,
Spain, Italy, Slovenia and France and compared with
285 patients with seropositive APS (table 1). Seronegative
APS had mostly obstetrical phenotypes rather than
venous thrombosis, with only 6% having experienced
a venous thrombosis. Non-criteria APL in seronegative
APS were anti-β2GPI IgA antibodies (n=3/127), anti-
annexin V antibodies (n=43/185), anti-PE IgG (n=19/
124) and IgM antibodies (n=43/124), anti-PS/PT IgG
(n=66/186) and IgM antibodies (n=69/186), without
any IgA aCL (n=0/53) or anti-vimentin antibodies
(n=0/65) (online supplemental table 1). A single non-
criteria APL was noted in 131 women (70%), with double
and triple positivity’s in 50 (27%) and 6 cases (3%),
respectively. Single-triple and double-triple positive sero-
negative APS have similar age and frequencies of obste-
trical ad thrombotic APS features (data not shown).
Comparing pregnancy outcomes of seronegative APS,
women with double-positive non-criteria APL had signifi-
cantly more frequent fetal loss than single-positive APS
(13/28 (46%) vs 16/70 (23%); p=0.03) despite the use of
similar frequencies of aspirin, low-molecular weighted
heparin (LMWH) and additional therapies during the
pregnancies.
The cumulative incidence of adverse obstetrical events
was significantly improved in treated seronegative APS
versus untreated ones (log rank <0.05), whereas there
was no difference between patients who received aspirin
or aspirin-LMWH combination (figure 1). The rates of
live-birth pregnancies treated with aspirin-LMWH combi-
nation were significantly higher than pregnancies result-
ing in fetal loss (46/75 (61%) vs 16/43 (37%), p=0.002).
Women with isolated recurrent miscarriages treated by
aspirin and LMWH combination (n=48 pregnancies;
89%) have live birth pregnancies in 31 (57%), whereas
those with prematurity related to placental insufficiency
under aspirin and LMWH in 9 (45%) have live birth
pregnancies in 18 (82%).
The control group of seropositive APS included 285
women with a mean age of 36±5 years. The APL were
the LA (n=211; 74%), aCL (n=228; 80%) and anti-
β2GPI antibodies (183 cases; 64%), with triple positivity







Caucasian (n; %) 150 (82) 188 (66)
Age (years) 33±5 36±5†
Obesity (n; %) 15 (9) 32 (11)
Arterial hypertension
(n; %)
3 (2) 54 (19)†
Diabetes mellitus (n; %) 1 (1) 18 (6)†






0/1 (1) 8 (3)/10 (4)†
APS features
Thrombotic APS
Arterial APS (n; %) 0 105 (37)†
Venous APS (n; %) 9 (6) 154 (54)†
Obstetrical APS (n; %) 168 (89) 89 (31)†
Mix APS (n; %) 8 (4) 16 (6)
Non-criteria features
(n; %)
16 (9) 141 (49)†
Obstetrical history
Miscarriages (n; %) 66 (35) 18 (6)†
Intrauterine deaths
(n; %)




43 (23) 31 (11)†
†p<0.05.
Values are numbers with frequencies and means with SD.
APS, antiphospholipid syndrome.
Figure 1 Adverse obstetrical events (fetal loss and/or
premature birth before the 34 weeks of gestation because of
eclampsia or severe preeclampsia or placental insufficiency) in
109 pregnancies of seronegative APS depending on treatment
during the pregnancy and the type (aspirin or aspirin/LMWH
combination). APS, antiphospholipid syndrome; LMWH,
low-molecular weighted heparin.
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observed in 134 women (47%). Seropositive APS women
had significantly more venous and/or arterial thrombosis
than seronegative APS women (table 1). Cardiovascular
risk factors including arterial hypertension, dyslipidae-
mia, and/or diabetes mellitus were significantly more
frequent in seropositive APS patients, and the latter
have more non-criteria APS manifestations (livedo race-
mosa, thrombocytopenia and migraines). Seronegative
APS women were more prone to have obstetrical pheno-
types, with more frequent intrauterine deaths, miscar-
riages and early prematurity (table 1).
For the comparisons of subsequent pregnancies follow-
ing APS diagnoses, we included 108 seronegative APS and
75 seropositive APS women, who had at least one preg-
nancy after APS diagnosis (table 2). The frequencies of
treated pregnancies and rates of aspirin-LMWH combina-
tion, prednisone and hydroxychloroquine used during
the pregnancy were not significantly different in serone-
gative and seropositive APS, except for higher rates of
curative LMWH use in seropositive APS and of aspirin
alone in seronegative APS. Cumulative incidence of
adverse obstetrical events was similar in seronegative
and seropositive APS patients (figure 2), although higher
rates of intrauterine deaths (15% vs 5%; p=0.03), pree-
clampsia (7% vs 16%, p=0.048) and lower live birth term
(36±3 vs 38±3 weeks of gestation; p=0.04) were noted in
seropositive treated APS.
Then, we analysed factors associated with fetal loss
(<10 weeks of gestation), intrauterine deaths (>10 weeks
of gestation), premature birth (<34 weeks of gestation)
and preeclampsia/HELLP syndrome considering all
pregnancies of both seropositive and seronegative APS
women. The factors analysed in univariate analysis for
these different obstetrical outcomes included: age, sero-
positive or seronegative APS status, cardiovascular risk
factors (obesity, arterial hypertension, diabetes, tobacco
use, hereditary thrombophilia), clinical APS phenotype
(thrombotic, obstetrical or mix), presence of non-criteria
APS features (livedo, thrombocytopenia, headaches, Lib-
man–Sachs endocarditis, etc.), type of therapies during
the pregnancy (aspirin, LMWH and isocoagulant or cura-
tive amounts, prednisone, hydroxychloroquine), mater-
nal adverse obstetrical events (preeclampsia/HELLP,
thrombosis), fetal complication (IUGR, oligoamnios)
and term of delivery. Considering the risk of fetal loss
(<10 weeks of gestation), in multivariate analyses, no
differences have been shown with regard to seroposi-
tive/seronegative APL status and the history of previous
early miscarriage (OR 3.4 [1.34, 9.08] (p=0.01)) and
smoking (OR 4.70 [1.07, 21.01] (p=0.038)) were asso-
ciated with an increased risk of early fetal loss, while
aspirin was associated with a lower risk (OR 0.25 [0.1,
0.61] (p=0.003)). Considering intrauterine deaths
(>10 weeks of gestation), in multivariate analysis, only
previous history of intra-uterine death was significant
with OR 4.8 [1.6; 15.6] (p=0.006).
Considering preeclampsia and HELLP syndrome, in
multivariate analysis, the age at the APS diagnosis and
the preventive use of LMWH were associated with
decreased risk (OR at 0.89 [0.81, 0.98] (p=0.007) and
0.20 [0.03, 0.96] (p=0.02), respectively).
Table 2 Pregnancy outcome and treatment in











Arterial APS (n; %) 0 20 (27)†
Venous APS (n; %) 8 (7) 42 (56)†
Obstetrical APS (n; %) 93 (86) 36 (48)†
Mix APS (n; %) 6 (6) 18 (24)†
Non-criteria features
(n; %)
18 (17) 34 (45)†
Previous obstetrical history
Miscarriages (n; %) 49 (45) 8 (11)†
Intrauterine deaths
(n; %)
29 (27) 16 (21)
Prematurity <34 weeks
of gestation (n; %)
24 (22) 14 (19)
Subsequent pregnancy treatments
Aspirin (n; %)/aspirin alone 95 (88)/32 (30) 57 (76)†/2 (3)†
LMWH isocoagulant
amounts (n; %)
63 (58) 39 (52)
LMWH curative amounts
(n; %)
2 (2) 33 (44)†
Aspirin-LMWH (n; %) 65 (60) 55 (73)
Prednisone (n; %) 10 (9) 4 (5)
Hydroxychloroquine (n; %) 10 (9) 8 (11)








5 (5) 7 (10)
Oligoamnios (n; %) 2 (2) 1 (1)








Prematurity <34 weeks of
gestation (n; %)
6 (6) 9 (12)
Term of fetal loss (weeks of
gestation)
10±8 13±7
Live births (n; %) 75 (69) 53 (70)




Values are numbers with frequencies and means with SD.
APS, antiphospholipid syndrome; HELLP, hemolysis, Elevated
Liver enzymes and Low platelet count; LMWH, low-molecular
weighted heparin.
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Considering the occurrence of at least one adverse
obstetrical events among early fetal loss, intrauterine
deaths, premature birth and preeclampsia/HELLP syn-
drome, the multivariate analysis showed that aspirin use
(OR at 0.29 [0.11, 0.69]; p=0.003) was associated with
obstetrical outcomes, independently of seropositive or
seronegative APL status.
DISCUSSION
In this large European case-series of seronegative APS
with at least one detectable non-criteria APL, we
described clinical APS features and compared them to
seropositive APS. Seronegative APShave less frequent
thrombotic and non-criteria features than seropositive
APS. Pregnancy outcomes of seronegative APS were man-
aged similarly to seropositive APS especially with a similar
use of isocoagulant LMWHand combined aspirin-LMWH
treatment during the pregnancy and associated with bet-
ter obstetrical outcomes in seronegative APS women than
no treatment.
Patients with clinical features of APS considering
Sydney criteria but with negative APL tests are quite
usual, and the diagnosis of seronegative APS has
been introduced for these patients by Hughes and
Khamashta in 2003.9 10 In this study, 67 patients
with major clinical APS criteria and at least two addi-
tional non-criteria features without conventional APL
were compared with seropositive APS (n=87).10
Thrombotic and obstetrical features were similar in
both seronegative and seropositive APS patients, ser-
onegative APS tended to have more pregnancy mor-
bidity, and non-conventional APL have not been
tested in this study. Other studies described serone-
gative APS considering only major clinical APS cri-
teria, without adding APS non-criteria features, with
mainly clinical APS features and not all having at
least one detectable non-criteria APL. Seronegative
APS have been found to present more frequent
obstetrical features, in particular recurrent miscar-
riages in another case-series, but only with 37% of
patients that have detectable non-criteria APL.11
A major limitation of seronegative APS studies is
actually the heterogeneity of tested non-criteria
APL, the clinical inclusion criteria, the absence of
diagnostic criteria; studies of seronegative APS with
at least on detectable non-criteria APL are lacking.
Non-criteria APL have also been evaluated in seropo-
sitive APS patients, considering the potential use to
define high-risk subgroups. Thus, anti-PS/PT antibo-
dies have been shown to be associated to adverse
pregnancy outcome,12 and included in the GAPSS
scale, defining the relapse risk for thrombotic
APS.13 Among APS women seeking conception, anti-
PS/PT antibodies have been found to be an interest-
ing marker for APL-related complications, in particu-
lar for IUGR.14 The prevalence of different non-criteria
APL in our study varied from 0% for anti-vimentin
and IgA aCL antibodies to 37% for anti-PS/PT autoan-
tibodies and could be useful to consider in routine
screening of the seronegative APS.
In our case series, more than 80% of seronegative APS
women have received aspirin and/or LMWH combina-
tion during the pregnancy, with a similar rate of com-
bined aspirin-LMWH to seropositive APS. Seropositive
APS seems to have poorer obstetrical outcome, despite
more prevalent curative APS amounts. Moreover,
whether combined aspirin-LMWH treatment signifi-
cantly reduces placenta-mediated complications in
women receiving low-dose aspirin for previous severe
preeclampsia diagnosed before 34 weeks of gestation
and no previously recognised APS has been
challenged.15 16 Data about the management of serone-
gative APS are quite scarce. We previously reported 65
patients with seronegative APS with at least one non-
criteria APL, compared with 83 seropositive APS and
to the control group without any APL.17 The conven-
tional aspirin/heparin combination was significantly
associated with live births in both seropositive and ser-
onegative APS groups, at the difference of women with-
out any detectable APL. Our study provides data about
the management of seronegative APS during the preg-
nancy and shows the benefit of aspirin alone or com-
bined with LMWH to prevent adverse obstetrical
outcomes. Prospective studies are lacking to determine
the value and the types of therapies for seronegative
APS, in particular the need for prophylactic vitamin
K antagonists therapies in thrombotic seronegative APS.
Some important limitations should be discussed
such as the retrospective design, the possible inclusion
of mainly obstetrical subtypes and the absence of
Figure 2 Adverse obstetrical events (fetal loss and/or
premature birth before the 34 weeks of gestation because of
eclampsia or severe preeclampsia or placental insufficiency)
among 183 pregnancies depending on APS seropositive and
seronegative status. APS, antiphospholipid syndrome.
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centralised screening of both conventional and non-
criteria APL in our cases. Seronegative and seropositive
APS were not matched which can account for the differ-
ences which have been noted between these groups.
Even thrombotic and obstetrical APS should be
included, the need for at least one pregnancy, more
frequent non-criteria APL screening after adverse obste-
trical event probably could biased the prevalence of
thrombotic subtypes. APS is still a diagnostic challenge,
as no international standardised laboratory tests are
available, and it is also conceivable that positive APL
becomes negative over the time. Despite these important
limitations, one has to consider that, previously, anti-
B2GPI have been added to the laboratory criteria of
APS and that new autoantigens target antibodies could
be an additional tool to help to the APS diagnosis.11
According to the different prevalent of these non-
criteria APL, in particular, for IgA and anti-vimentin
antibodies, the screening of non-criteria APL could be
organised in ‘step by step’ approach.
CONCLUSION
Several non-criteria APL can be detected in patients with
clinical features consistent with APS without any conven-
tional APL, with various prevalent rates. The detection of
non-criteria APL and thus the diagnosis of seronegative APS
could discuss the therapeutic management similar to sero-
positive APS, but well-designed controlled studies are
necessary.
Author affiliations
1Sorbonne Université, AP-HP, Hôpital Saint-Antoine, Service de Médecine Interne
and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Paris,
France
2Department of Internal Medicine, AP-HP Nord, Beaujon Hospital, Paris University,
Clichy, France
3Department of Surgical Sciences, Obstetrics and Gynecology, University of Torino,
Turin, Italy
4Department of Internal Medicine, Althaia Network Health, Manresa, Barcelona,
Spain
55Autoimmune, Thrombophilic Diseases and Pregnancy Section, Acute Hospital “Dr
Carlos G Durand”, Buenos Aires, Argentina
6Department of Immunology, Hospital Universitario 12 de Octubre and Research
Institute, Madrid, Spain
7Department of Internal Medicine, Vascular and Thrombosis Unit, Rouen University
Hospital, Normandie University, UNIROUEN, INSERM, Rouen, France
8Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria
9Service Department of internal medicine, CHU d’Angers, Angers, France
10Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana,
Slovenia
11Département de Médecine Vasculaire, Médecine Interne et Pneumologie, CHU de
Brest, Hôpital La Cavale Blanche, Brest Cedex, France
12EA 3878, GETBO, Université Bretagne Loire, Brest Cedex, France
13Department of Medicine-DIMED, Rheumatology Unit, University of Padua, Padua,
Italy
14Department of Internal Medicine, University Hospital of Limoges, Limoges, France
15Department of Obstetrics, Gynecology and Reproductive Medicine Centers,
Hôpitaux Universitaires Paris Seine Saint-Denis, Assistance Publique-Hôpitaux de
Paris, Bondy, France
16University of Paris 13, Sorbonne University,Bobigny, France
17Service de Gynécologie Obstétrique, Hôpital Trousseau, AP-HP, Paris, France
18Sorbonne Université,Paris, France
19Department of Gynaecology and Obstetrics and Reproductive Medicine, Tenon
Hospital, Assistance Publique – Paris Hospitals,Paris, France
20Service de Médecine Interne et Immunologie Clinique, Centre de Référence des
Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest (CeRAINO), Univ.
Lille, CHU Lille, Lille, France
21Department of Immunology, AP-HP, Hôpital Saint Antoine,Paris, France
22Immunology Department, Bichat Hospital, APHP, Paris, France
23Department of Internal Medicine, University Hospital of Amiens, Amiens, France
24Université de Paris, INSERM UMR_S1148, Paris cedex 18, France
25Laboratoire d’Hématologie, AP-HP, Hôpital Bichat, Paris cedex 18, France
26Systemic Autoimmune Diseases Unit, Department of Internal Medicine-1, Vall
d’Hebron University Hospital, Barcelona, Spain
27Department of Medicine, Faculty of Medicine, Universitat Autönoma de Barcelona,
Barcelona, Spain
Acknowledgements We thank the European Forum on Antiphospholipid Antibodies
for his help in this study.
Contributors All authors were involved in drafting the article. NAand AM have full
access to all data in the study and takes responsibility for the integrity of the data and
the accuracy of data analysis. Study conception and design: NA, YN, LM, EEV, CDM,
PB, DEP, LC, GK, MB, CJ, PNR, GU, PZ, HB, KP, YB, JAR, OF, AM. Acquisition of data:
NA, YN, LM, EV, CDM, PB, DEP, LC, GK, MB, CJ, PNR, GU, PZ, HB, KP, YB, JAR, OF,
AM. Analysis and interpretation of data: NA, YN, MA, OF, AM.
Funding The authors have not declared a specific grant for this research from any
funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval Ethical committee not required for this observational study
according to Helsinki law.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available in a public, open access repository.
Supplemental material This content has been supplied by the author(s). It has
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have
been peer-reviewed. Any opinions or recommendations discussed are solely
those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability
and responsibility arising from any reliance placed on the content. Where the
content includes any translated material, BMJ does not warrant the accuracy
and reliability of the translations (including but not limited to local regulations,
clinical guidelines, terminology, drug names and drug dosages), and is not
responsible for any error and/or omissions arising from translation and adap-
tation or otherwise.
Open access This is an open access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the use







1 Mekinian A, Costedoat-Chalumeau N, Masseau A, et al. Obstetrical
APS: is there a place for hydroxychloroquine to improve the pregnancy
outcome? Autoimmun Rev 2015;14:23–9.
2 Nayfe R, Uthman I, Aoun J, et al. Seronegative antiphospholipid
syndrome. Rheumatology (Oxford) 2013;52:1358–67.
3 Alessandri C, Conti F, Pendolino M, et al. New autoantigens in the
antiphospholipid syndrome. Autoimmun Rev 2011;10:609–16.
4 Litvinova E, Darnige L, Kirilovsky A, et al.Prevalence and significance of
non-conventional antiphospholipid antibodies in patients with clinical
APS criteria. Front Immunol 2018;9:2971.
5 Zhu H, Wang M, Dong Y, et al. Detection of non-criteria
autoantibodies in women without apparent causes for pregnancy
loss. 2019:e22994.
RMD Open
















pen: first published as 10.1136/rm





6 Truglia S, Capozzi A,Mancuso S, et al.Amonocentric cohort of obstetric
seronegative anti-phospholipid syndrome. Front Immunol 2018;9:1678.
7 Conti F, Andreoli L, Crisafulli F, et al. Does seronegative obstetric APS
exist? “pro” and “cons”. Autoimmun Rev 2019;18:102407.
8 Alijotas-Reig J, Ferrer-Oliveras R, Ruffatti A, et al. The European
Registry on Obstetric Antiphospholipid Syndrome (EUROAPS):
a survey of 247 consecutive cases. Autoimmun Rev 2015;14:387–95.
9 Hughes GR, Khamashta MA. Seronegative antiphospholipid
syndrome. Ann Rheum Dis 2003;62:1127.
10 Rodriguez-Garcia JL, Bertolaccini ML, Cuadrado MJ, et al. Clinical
manifestations of antiphospholipid syndrome (APS) with and without
antiphospholipid antibodies (the so-called ‘seronegative APS’). Ann
Rheum Dis 2012;71:242–4.
11 Zohoury N, Bertolaccini ML, Rodriguez-Garcia JL, et al. Closing the
serological gap in the antiphospholipid syndrome: the value of
“non-criteria” antiphospholipid antibodies. J Rheumatol
2017;44:1597–602.
12 Zigon P, Perdan Pirkmajer K, Tomsic M, et al. Anti-phosphatidylserine
/prothrombin antibodies are associated with adverse pregnancy
outcomes. J Immunol Res 2015;2015:975704.
13 Sciascia S, Sanna G, Murru V, et al. GAPSS: the global
anti-phospholipid syndrome score. Rheumatology (Oxford)
2013;52:1397–403.
14 Canti V, Del Rosso S, Tonello M, et al. Antiphosphatidylserine/
prothrombin antibodies in antiphospholipid syndrome with
intrauterine growth restriction and preeclampsia. J Rheumatol
2018;45:1263–72.
15 Haddad B, Winer N, Chitrit Y, et al. Enoxaparin and aspirin compared
with aspirin alone to prevent placenta-mediated pregnancy
complications: a randomized controlled trial. Obstet Gynecol
2016;128:1053–63.
16 Rodger MA, Hague WM, Kingdom J, et al. Antepartum dalteparin
versus no antepartum dalteparin for the prevention of pregnancy
complications in pregnant women with thrombophilia (TIPPS):
a multinational open-label randomised trial. Lancet (London, England)
2014;384:1673–83.
17 Mekinian A, Bourrienne MC, Carbillon L, et al. Non-conventional
antiphospholipid antibodies in patients with clinical obstetrical APS:
prevalence and treatment efficacy in pregnancies. Semin Arthritis
Rheum 2016;46:232–7.
Connective tissue diseases
















pen: first published as 10.1136/rm
dopen-2020-001340 on 26 A
ugust 2020. D
ow
nloaded from
 
